相关实验视频

Updated: May 6, 2026

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

WDR35与肺腺癌的化学敏感性和预后有关

Liang Tang¹, Yinhui Xu², Xinmiao Zhang³

¹Department of Thoracic Surgery, Dazhou Central Hospital, Dazhou, China.

Cancer biotherapy & radiopharmaceuticals

|June 23, 2025

概括

WD重复域35 (WDR35) 在正常的肺组织中高度表达,并且与肺腺癌患者更好的化疗反应和存活率有关. 这一发现为肺癌治疗策略提供了新的见解.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
遗传学遗传学是一个

背景情况:

肺腺癌 (LUAD) 在治疗和预后方面具有重大挑战.
确定用于化疗敏感性和患者结果的新生物标志物至关重要.

研究的目的:

在LUAD中调查WD重复域35 (WDR35) 的表达模式.
确定WDR35与化疗敏感性和患者预后的关联.

主要方法:

利用随机森林和支持矢量机算法来识别关键基因.
在LUAD样本中的转录组和蛋白组水平上验证了WDR35表达.
进行药物敏感性分析,GSEA和Kaplan-Meier生存分析.

主要成果:

与LUAD组织相比,WDR35在正常的肺组织中表达高.
高WDR35表达与对化疗剂敏感性增加相关.
较高的WDR35水平与更好的整体和疾病特异性生存率有关.

结论:

WDR35作为一种潜在的生物标志物,用于预测LUAD中的化疗反应.
WDR35表达与肺腺癌患者的预后改善有关.

关键词:

这就是WDR35的WDR35.生物标志物生物标志物化学敏感性化学敏感性肺部腺癌的癌症.预后预后预后

更多相关视频

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

相关概念视频

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...